Glycolipid Disialoganglioside-directed Antibody class drugs
2 results
Danyelza (naxitamab)
(Naxitamab)Y-mAbs Therapeutics, Inc.
Usage: DANYELZA is indicated for treating pediatric patients (1 year and older) and adults with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow, in conjunction with GM-CSF, after showing a partial response, minor response, or stable disease to prior therapies.
Unituxin (dinutuximab)
(DINUTUXIMAB)United Therapeutics Corporation
Usage: Unituxin (dinutuximab) is indicated for use, alongside GM-CSF, IL-2, and 13-cis-retinoic acid, in pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior first-line multiagent, multimodality therapy.